ARCHIVES

Samuel Broder Plans To Leave Celera.

This article is from The Cancer Letter archive.

Vol. 36 No. 32 | September 10, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Oncology Unit Fastest in Approvals Despite Having Highest Workload

May 9, 2014

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Ethics rules slammed by NIH scientists, institute directors, societies, Senators.

April 8, 2005

NCI Critics Take Their Best Shots, Seek New Emphasis On Prevention At Kennedy Hearings

March 16, 1979

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

New: Special Reports on the Dialogue and NCI’s 2015 goal posted at cancerletter.com.

August 8, 2003